Early Effects of Single and Low-Frequency Repeated Administration ofTeriparatide, hPTH(1-34), on Bone Formation and Resorption in Ovariectomized Rats
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605520798 | ||
| 003 | CHVBK | ||
| 005 | 20210128100737.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20151001xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s00223-015-0026-1 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s00223-015-0026-1 | ||
| 245 | 0 | 0 | |a Early Effects of Single and Low-Frequency Repeated Administration ofTeriparatide, hPTH(1-34), on Bone Formation and Resorption in Ovariectomized Rats |h [Elektronische Daten] |c [Yukihiro Isogai, Ryoko Takao-Kawabata, Aya Takakura, Emika Sugimoto, Osamu Nakazono, Ichiro Ikegaki, Hiroshi Kuriyama, Toshinori Ishizuya] |
| 520 | 3 | |a Intermittent repeated administration of teriparatide (TPTD) has potent anabolic effects on bones in vivo. However, TPTD has both anabolic and catabolic effects on osteoblasts in vitro, and the mechanisms underlying its promotion of bone formation are unclear. This study aimed to elucidate the time-dependent changes in bone formation and resorption by examining changes in bone turnover markers and bone tissue over time after TPTD administration with low frequency in ovariectomized rats. The amount of serum osteocalcin, a bone formation marker, was transiently reduced after single TPTD administration, but increased thereafter, remaining increased for several days. In contrast, the amount of excreted urinary C-telopeptide, a bone resorption marker, increased transiently after single TPTD administration, and subsequently returned to control levels on the day after administration. Tissue histomorphometric analyses conducted 8h after administration showed no changes in bone formation or bone resorption parameters. However, at 48h, the bone formation parameters OS/BS and Ob.S/BS were increased, while the bone resorption parameter ES/BS was decreased. After repeated TPTD administration for 4weeks, OS/BS, Ob.S/BS, and MS/BS increased, while Oc.S/BS decreased. Serum osteocalcin at 4weeks after repeated administration was significantly correlated with OS/BS and Ob.S/BS. These present findings indicate that TPTD has dual, time-dependent effects on bone resorption and bone formation. Immediately after single administration, there was transient promotion of bone resorption and suppression of bone formation. However, sustained stimulation of bone formation occurred thereafter. Furthermore, these data suggest that this sustained bone formation led to anabolic effects with repeated TPTD administration. | |
| 540 | |a The Author(s), 2015 | ||
| 690 | 7 | |a Teriparatide |2 nationallicence | |
| 690 | 7 | |a Bone turnover marker |2 nationallicence | |
| 690 | 7 | |a Bone formation |2 nationallicence | |
| 690 | 7 | |a Bone resorption |2 nationallicence | |
| 690 | 7 | |a Histomorphometry |2 nationallicence | |
| 700 | 1 | |a Isogai |D Yukihiro |u Laboratory for Pharmacology, Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, 410-2321, Izunokuni-shi, Shizuoka, Japan |4 aut | |
| 700 | 1 | |a Takao-Kawabata |D Ryoko |u Laboratory for Pharmacology, Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, 410-2321, Izunokuni-shi, Shizuoka, Japan |4 aut | |
| 700 | 1 | |a Takakura |D Aya |u Laboratory for Pharmacology, Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, 410-2321, Izunokuni-shi, Shizuoka, Japan |4 aut | |
| 700 | 1 | |a Sugimoto |D Emika |u Laboratory for Pharmacology, Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, 410-2321, Izunokuni-shi, Shizuoka, Japan |4 aut | |
| 700 | 1 | |a Nakazono |D Osamu |u Laboratory for Pharmacology, Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, 410-2321, Izunokuni-shi, Shizuoka, Japan |4 aut | |
| 700 | 1 | |a Ikegaki |D Ichiro |u Laboratory for Pharmacology, Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, 410-2321, Izunokuni-shi, Shizuoka, Japan |4 aut | |
| 700 | 1 | |a Kuriyama |D Hiroshi |u Laboratory for Pharmacology, Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, 410-2321, Izunokuni-shi, Shizuoka, Japan |4 aut | |
| 700 | 1 | |a Ishizuya |D Toshinori |u Laboratory for Pharmacology, Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, 410-2321, Izunokuni-shi, Shizuoka, Japan |4 aut | |
| 773 | 0 | |t Calcified Tissue International |d Springer US; http://www.springer-ny.com |g 97/4(2015-10-01), 412-420 |x 0171-967X |q 97:4<412 |1 2015 |2 97 |o 223 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00223-015-0026-1 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s00223-015-0026-1 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Isogai |D Yukihiro |u Laboratory for Pharmacology, Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, 410-2321, Izunokuni-shi, Shizuoka, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Takao-Kawabata |D Ryoko |u Laboratory for Pharmacology, Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, 410-2321, Izunokuni-shi, Shizuoka, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Takakura |D Aya |u Laboratory for Pharmacology, Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, 410-2321, Izunokuni-shi, Shizuoka, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Sugimoto |D Emika |u Laboratory for Pharmacology, Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, 410-2321, Izunokuni-shi, Shizuoka, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Nakazono |D Osamu |u Laboratory for Pharmacology, Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, 410-2321, Izunokuni-shi, Shizuoka, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ikegaki |D Ichiro |u Laboratory for Pharmacology, Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, 410-2321, Izunokuni-shi, Shizuoka, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kuriyama |D Hiroshi |u Laboratory for Pharmacology, Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, 410-2321, Izunokuni-shi, Shizuoka, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ishizuya |D Toshinori |u Laboratory for Pharmacology, Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, 410-2321, Izunokuni-shi, Shizuoka, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Calcified Tissue International |d Springer US; http://www.springer-ny.com |g 97/4(2015-10-01), 412-420 |x 0171-967X |q 97:4<412 |1 2015 |2 97 |o 223 | ||